Chronic Disease and Immunosuppression Increase the Risk for Nonvaccine Serotype Pneumococcal Disease: A Nationwide Population-based Study.
Streptococcus pneumoniae
immunodeficiency
invasive pneumococcal disease
pneumococcal conjugate vaccines
serotypes
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
28 04 2022
28 04 2022
Historique:
received:
06
02
2021
pubmed:
25
7
2021
medline:
3
5
2022
entrez:
24
7
2021
Statut:
ppublish
Résumé
Demography is changing, with people living longer with comorbidities. In this nationwide population-based study, we investigated the serotype-specific invasive pneumococcal disease (IPD) risk in individuals with comorbidities, and effects of the pneumococcal conjugated vaccine (PCV) child immunization program. Cases included 14 096 IPD episodes in Sweden during 2006-2015. Controls (n = 137 289), matched to cases by age, sex, region, and calendar time, were selected from the general population. Comorbidity data was obtained through health registers and grouped as immunocompromising (IC) or chronic medical conditions (CMC). The prevalence of CMC and IC among elderly cases was 33.9% and 39.4%. New risks identified for IPD were sarcoidosis, inflammatory polyarthropathies, systemic connective tissue, and neurological diseases. The odds ratio (OR) for IPD caused by non-PCV13 compared with PCV13 serotypes was higher in individuals with CMC/IC. Serotypes associated with the highest risk were 16F, 15C, 35F, 19F, and 23A (OR 3-5 for CMC, >10 for IC). Most comorbidities increased post-vaccination, and absolute increases of IPD caused by non-PCV13, PPV23-non-PCV13, and non-PCV13/non-PPV23 serotypes were higher in individuals with IC/CMC compared with healthy persons. Non-PCV13 serotypes 6C, 9N, 11A, 22F, 23A and 35F increased more in those with comorbidities. Mortality due to non-PCV13 serotypes increased in individuals with IC/CMC, while remaining stable in persons without comorbidities. The PCV child immunization program associates with an increased disease burden of non-vaccine serotypes in individuals with comorbidities. These data are important for vaccine design and optimization of current vaccination strategies.
Sections du résumé
BACKGROUND
Demography is changing, with people living longer with comorbidities. In this nationwide population-based study, we investigated the serotype-specific invasive pneumococcal disease (IPD) risk in individuals with comorbidities, and effects of the pneumococcal conjugated vaccine (PCV) child immunization program.
METHODS
Cases included 14 096 IPD episodes in Sweden during 2006-2015. Controls (n = 137 289), matched to cases by age, sex, region, and calendar time, were selected from the general population. Comorbidity data was obtained through health registers and grouped as immunocompromising (IC) or chronic medical conditions (CMC).
RESULTS
The prevalence of CMC and IC among elderly cases was 33.9% and 39.4%. New risks identified for IPD were sarcoidosis, inflammatory polyarthropathies, systemic connective tissue, and neurological diseases. The odds ratio (OR) for IPD caused by non-PCV13 compared with PCV13 serotypes was higher in individuals with CMC/IC. Serotypes associated with the highest risk were 16F, 15C, 35F, 19F, and 23A (OR 3-5 for CMC, >10 for IC). Most comorbidities increased post-vaccination, and absolute increases of IPD caused by non-PCV13, PPV23-non-PCV13, and non-PCV13/non-PPV23 serotypes were higher in individuals with IC/CMC compared with healthy persons. Non-PCV13 serotypes 6C, 9N, 11A, 22F, 23A and 35F increased more in those with comorbidities. Mortality due to non-PCV13 serotypes increased in individuals with IC/CMC, while remaining stable in persons without comorbidities.
CONCLUSIONS
The PCV child immunization program associates with an increased disease burden of non-vaccine serotypes in individuals with comorbidities. These data are important for vaccine design and optimization of current vaccination strategies.
Identifiants
pubmed: 34302732
pii: 6327794
doi: 10.1093/cid/ciab651
pmc: PMC9049269
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1338-1349Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Infect. 2012 Jul;65(1):17-24
pubmed: 22394683
N Engl J Med. 1991 Nov 21;325(21):1453-60
pubmed: 1944423
EClinicalMedicine. 2019 Jan 02;6:42-50
pubmed: 31193709
Clin Infect Dis. 2019 Apr 8;68(8):1367-1373
pubmed: 30957160
PLoS One. 2015 Nov 30;10(11):e0143084
pubmed: 26619340
BMC Infect Dis. 2008 Jul 22;8:96
pubmed: 18647385
J Infect Dis. 2005 Aug 1;192(3):377-86
pubmed: 15995950
Clin Infect Dis. 2017 Nov 13;65(11):1780-1789
pubmed: 29020171
Microb Drug Resist. 2003 Winter;9(4):337-44
pubmed: 15008138
JAMA. 1993 Oct 20;270(15):1826-31
pubmed: 8411526
Thorax. 2019 May;74(5):473-482
pubmed: 30355641
Clin Infect Dis. 2019 Jun 18;69(1):100-106
pubmed: 30321313
J Intern Med. 2019 Dec;286(6):689-701
pubmed: 31278792
MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9
pubmed: 23051612
Clin Infect Dis. 2013 Dec;57(12):1722-30
pubmed: 24065334
Clin Infect Dis. 2006 Feb 15;42(4):451-9
pubmed: 16421787
Eur Respir J. 2016 Apr;47(4):1208-18
pubmed: 26797033
Clin Infect Dis. 2016 Jun 15;62(12):1521-6
pubmed: 27105745
Lancet Public Health. 2019 Mar;4(3):e159-e167
pubmed: 30851869
Lancet Infect Dis. 2015 Mar;15(3):301-9
pubmed: 25656600
Clin Infect Dis. 2016 Jan 15;62(2):139-47
pubmed: 26354970
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
Lancet Respir Med. 2017 Aug;5(8):648-656
pubmed: 28359798
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Vaccine. 2016 Aug 31;34(38):4565-4571
pubmed: 27473304
Clin Infect Dis. 2020 Jun 10;70(12):2484-2492
pubmed: 31402387
BMC Med. 2020 Mar 20;18(1):41
pubmed: 32192480